Professor of Medicine
Oncology
Dr. Cynthia G. Leichman, MD
|
|
Give Review
Cynthia G. Leichman is an expert in the field of Oncology. She graduated from Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63 in research and 85 in primary care medicine She received awards:"CMS Meaningful Use Stage 1 Certification". Cynthia Leichman has written publications. She has 54 publications published with PubMed. The lastest paper is: 'Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.' She accepts all Medicare patients.
Publications
- Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
- Comparison of anal Cancer outcomes in public and private hospital patients treated at a single radiation oncology center.
- Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal Cancer.
- Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal Cancer.
- Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplati...
- Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for adva...
- Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal Cancer in patients receiving oxaliplatin, 5-flou...
- Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal Cancer: GI INT 0144.
- Adjuvant therapy for colon Cancer 2005: new options in the twenty-first century.
- Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
- Hypersensitivity Reactions to oxaliplatin: incidence and management.
- A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
- Definitive and neoadjuvant therapies for Esophageal and gastroEsophageal junction tumors: a look back and toward the future.
- Regional chemotherapy is indicated after surgical resection of coloRectal metastases to the liver: a debate.
- Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic Cancer.
- Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil ...
- Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal Cancer: dose-volume histogram analysis.
- Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced Cancer.
- Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal Cancer.
- Therapy of disseminated colorectal Cancer: the emerging role of intratumoral molecular biology.
- Predictive and prognostic markers in gastrointestinal Cancers.
- Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenoCarcinoma of the stomach.
- Challenges posed by non-random missing quality of life data in an advanced-stage colorectal Cancer clinical trial.
- ColoRectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
- Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic coloRectal carcinoma: A Southwest Oncolog...
- Schedule dependency of 5-fluorouracil.
- Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid Tumors.
- High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in coloRectal tumors is associated with nonresponse to 5-...
- Thymidylate synthase as a predictor of response.
- p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal Cancer: an analysis of response and survival.
- p53 and thymidylate synthase expression in untreated stage II colon Cancer: associations with recurrence, survival, and site.
- ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric Cancer patients receiving combination cisplatin and fluor...
- Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal Cancer response and resistance to protracted-infusion fluorouracil an...
- Systemic chemotherapy for gastric Carcinoma followed by postoperative intraperitoneal therapy: a final report.
- Phase I and pharmacokinetic study of Oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
- A pilot trial of continuous infusion 5-fluorouracil with levamisole for adjuvant therapy of colon Cancer.
- Thymidylate synthase mRNA level in adenoCarcinoma of the stomach: a predictor for primary tumor response and overall survival.
- Quantitation of intratumoral thymidylate synthase expression predicts for resistance to proTracted infusion of 5-fluorouracil and weekly leucovorin in disseminated col...
- Phase II study of fluorouracil and its modulation in advanced colorectal Cancer: a Southwest Oncology Group study.
- Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human coloRectal and gastric tumors.
- A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal Cancer.
- Intraperitoneal 5-fluoro-2''-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study.
- Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance.
- Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials.
- Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
- Phase II trial of amonafide in advanced pancreas Cancer. A Southwest Oncology Group study.
- Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal Cancer.
- Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric Cancer: a University of Southern California pilot program.
- Biological modification of proTracted infusion of 5-fluorouracil with weekly leucovorin. A dose seeking clinical trial for patients with disseminated gastrointestinal ...
- Phase I study of echinomycin.
- Nonoperative therapy for squamous-cell Cancer of the esophagus.
- Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.
- Phase II trial of tamoxifen in Malignant melanoma.
Schools
Wayne State University School Of Medicine
Detroit Genl Hospital
Wayne State University
Procedures Preformed
- Cancer Counseling
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Wayne State University School of Medicine
Hospital
-
NYU Langone Medical Center -
Bellevue Hospital Center
Drug Facts
| NPI NUMBER | 1245236827 | |
| NPPES Provider LastName | LEICHMAN | |
| NPPES Provider FirstName | CYNTHIA | |
| NPPES Provider ZIPCode | 922701739 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 83.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1245236827 |
| Last Name Of The Provider | LEICHMAN |
| First Name Of The Provider | CYNTHIA |
| View All |
Similar Doctors
|
Dr. Davood Vafai, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Varun Gupta, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Arun K. Kalra, MD |
|
Dr. Jason S. Weisstein, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Luther D. Glenn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Petr Cech, MD |